S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Better Than Oil Stocks (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
MILAN FASHION PHOTOS: Gucci sparkles as De Sarno hits stride
Claim $10,000 In FREE silver In 2024 (Ad)
Google says its AI image-generator would sometimes 'overcompensate' for diversity
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Better Than Oil Stocks (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
MILAN FASHION PHOTOS: Gucci sparkles as De Sarno hits stride
Claim $10,000 In FREE silver In 2024 (Ad)
Google says its AI image-generator would sometimes 'overcompensate' for diversity
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Better Than Oil Stocks (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
MILAN FASHION PHOTOS: Gucci sparkles as De Sarno hits stride
Claim $10,000 In FREE silver In 2024 (Ad)
Google says its AI image-generator would sometimes 'overcompensate' for diversity
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Better Than Oil Stocks (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
MILAN FASHION PHOTOS: Gucci sparkles as De Sarno hits stride
Claim $10,000 In FREE silver In 2024 (Ad)
Google says its AI image-generator would sometimes 'overcompensate' for diversity
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions

eFFECTOR Therapeutics (EFTR) News Today

$11.12
+0.08 (+0.72%)
(As of 02/23/2024 ET)
SourceHeadline
markets.businessinsider.com logoBuy Rating Affirmed for eFFECTOR Therapeutics Amid Promising Oncology Drug Milestones and Extended Financial Runway
markets.businessinsider.com - February 6 at 9:21 PM
msn.com logoeFFECTOR Therapeutics Regains Nasdaq Compliance Status
msn.com - January 31 at 2:01 PM
finance.yahoo.com logoDoes eFFECTOR Therapeutics, Inc. (EFTR) Have the Potential to Rally 814.53% as Wall Street Analysts Expect?
finance.yahoo.com - January 30 at 12:44 PM
finance.yahoo.com logoeFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
finance.yahoo.com - January 25 at 6:53 PM
marketbeat.com logo
marketbeat.com - January 12 at 6:00 AM
finanznachrichten.de logoeFFECTOR Therapeutics, Inc.: eFFECTOR Therapeutics Announces Reverse Stock Split
finanznachrichten.de - January 10 at 9:32 AM
msn.com logoeFFECTOR Therapeutics announces 1-for-25 reverse stock split
msn.com - January 9 at 12:17 PM
msn.com logoeFFECTOR Therapeutics Discloses Updated Data From Mid-Stage Breast Cancer Study
msn.com - December 8 at 3:04 PM
finance.yahoo.com logoeFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients
finance.yahoo.com - December 8 at 10:04 AM
msn.com logoeFFECTOR stock rises after FDA fast track status for breast cancer therapy
msn.com - November 28 at 10:40 AM
markets.businessinsider.com logoBuy Rating for eFFECTOR Therapeutics Based on Promising Drug Developments and Capital Security
markets.businessinsider.com - November 17 at 9:59 AM
msn.com logoeFFECTOR Therapeutics GAAP EPS of -$0.13 misses by $0.01
msn.com - November 13 at 7:57 PM
tmcnet.com logoeFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
tmcnet.com - November 13 at 7:57 PM
fool.com logoeFFECTOR Therapeutics (NASDAQ: EFTR)
fool.com - September 20 at 7:50 PM
msn.com logoHC Wainwright starts eFFECTOR at buy, cites drug technology platform
msn.com - August 25 at 10:45 PM
nasdaq.com logoHC Wainwright & Co. Initiates Coverage of eFFECTOR Therapeutics (EFTR) with Buy Recommendation
nasdaq.com - August 24 at 10:36 PM
markets.businessinsider.com logoeFFECTOR Stock To Rally Over 500%? Analyst Predict Blockbuster Status For Cancer Candidates
markets.businessinsider.com - August 24 at 5:36 PM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: eFFECTOR Therapeutics (EFTR) and Brainsway (BWAY)
markets.businessinsider.com - August 24 at 6:52 AM
benzinga.com logoeFFECTOR Therapeutics Chief Executive Officer Acquires 33,799 Shares After Exercising Company Stock Options
benzinga.com - August 14 at 6:44 PM
finance.yahoo.com logoeFFECTOR Therapeutics First Half 2023 Earnings: US$0.41 loss per share (vs US$0.093 loss in 1H 2022)
finance.yahoo.com - August 11 at 6:34 PM
markets.businessinsider.com logoMizuho Securities Reaffirms Their Buy Rating on eFFECTOR Therapeutics (EFTR)
markets.businessinsider.com - August 9 at 12:57 AM
finance.yahoo.com logoeFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
finance.yahoo.com - August 8 at 7:55 PM
finance.yahoo.com logoeFFECTOR Therapeutics Raises a Total of $16.2 Million in Gross Proceeds from Two Recent Registered Direct Offerings
finance.yahoo.com - June 8 at 4:40 PM
msn.com logoeFFECTOR Therapeutics to launch ~$8.7M registered direct offering
msn.com - June 7 at 10:17 AM
marketwatch.com logoeFFECTOR Therapeutics Shares Fall Premarket After Stock Sale >EFTR
marketwatch.com - June 7 at 10:17 AM
finance.yahoo.com logoInvestors in eFFECTOR Therapeutics (NASDAQ:EFTR) from a year ago are still down 35%, even after 77% gain this past week
finance.yahoo.com - June 3 at 1:57 PM
finance.yahoo.com logoeFFECTOR Therapeutics Announces Closing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
finance.yahoo.com - May 31 at 6:27 PM
msn.com logoStifel Upgrades eFFECTOR Therapeutics (EFTR)
msn.com - May 26 at 11:02 PM
msn.com logoWhy eFFECTOR Therapeutics Shares Trading Higher Today
msn.com - May 26 at 1:01 PM
msn.com logoeFFECTOR soars as Stifel upgrades after Phase 2 data for cancer drug combo
msn.com - May 26 at 1:01 PM
finance.yahoo.com logoeFFECTOR Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
finance.yahoo.com - May 26 at 1:01 PM
investorplace.com logoWhy Is eFFECTOR Therapeutics (EFTR) Stock Up 75% Today?
investorplace.com - May 26 at 9:10 AM
markets.businessinsider.com logoeFFECTOR Therapeutics (EFTR) Gets a Buy from Mizuho Securities
markets.businessinsider.com - May 26 at 2:30 AM
tmcnet.com logoeFFECTOR Therapeutics Reports Positive Data Updates from Phase
tmcnet.com - May 25 at 9:24 PM
finance.yahoo.com logoeFFECTOR Therapeutics Reports Positive Data Updates from Phase 2 Expansion Cohorts Evaluating Zotatifin in Patients with ER+ Metastatic Breast Cancer at the ASCO 2023 Annual Meeting
finance.yahoo.com - May 25 at 9:24 PM
msn.com logoCredit Suisse Maintains eFFECTOR Therapeutics (EFTR) Outperform Recommendation
msn.com - May 12 at 8:08 PM
finanznachrichten.de logoeFFECTOR Therapeutics, Inc.: eFFECTOR Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
finanznachrichten.de - May 10 at 3:52 AM
markets.businessinsider.com logoeFFECTOR Therapeutics (EFTR) Receives a Buy from Mizuho Securities
markets.businessinsider.com - May 10 at 3:52 AM
msn.com logoRecap: eFFECTOR Therapeutics Q1 Earnings
msn.com - May 9 at 10:52 PM
finance.yahoo.com logoeFFECTOR Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
finance.yahoo.com - May 9 at 5:51 PM
finance.yahoo.com logoeFFECTOR to Present Updated Clinical Data from Phase 2 Expansion Cohorts for Zotatifin in Patients with ER+ Metastatic Breast Cancer at ASCO 2023 Annual Meeting
finance.yahoo.com - April 26 at 8:39 PM
msn.com logoeFFECTOR Therapeutics Collaborates With Stanford Medicine Mid-Stage Breast Cancer Study
msn.com - April 11 at 10:58 AM
finanznachrichten.de logoeFFECTOR Therapeutics, Inc.: eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
finanznachrichten.de - March 9 at 8:54 AM
msn.com logoeFFECTOR Therapeutics GAAP EPS of -$0.22 beats by $0.02, revenue of $0.67M beats by $0.01M
msn.com - March 8 at 10:52 PM
markets.businessinsider.com logoMizuho Securities Keeps Their Buy Rating on eFFECTOR Therapeutics (EFTR)
markets.businessinsider.com - March 8 at 10:52 PM
msn.com logoUnited Therapeutics (UTHR) Q4 Earnings & Sales Miss Estimates
msn.com - February 23 at 4:14 PM
uk.finance.yahoo.com logoeFFECTOR Therapeutics Shares Fall After Data From COVID-19 Treatment Trial
uk.finance.yahoo.com - February 21 at 4:25 PM
finance.yahoo.com logoeFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID
finance.yahoo.com - February 21 at 11:25 AM
finance.yahoo.com logoeFFECTOR Therapeutics to Present at 2023 BIO CEO & Investor Conference
finance.yahoo.com - January 30 at 12:46 PM
finance.yahoo.com logoeFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin and General Corporate Update
finance.yahoo.com - January 5 at 5:19 PM
Get eFFECTOR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter.



EFTR Media Mentions By Week

EFTR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

EFTR
News Sentiment

0.00

0.43

Average
Medical
News Sentiment

EFTR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

EFTR Articles
This Week

0

0

EFTR Articles
Average Week

Get eFFECTOR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:EFTR) was last updated on 2/24/2024 by MarketBeat.com Staff